KARYOPHARM THERAPEUTICS
Karyopharm Therapeutics is a biopharmaceutical company focusing on the development of novel drugs for the treatment of cancer, inflammation and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and to evaluate them in subsequent human clinical studies.
KARYOPHARM THERAPEUTICS
Industry:
Health Care Medical Pharmaceutical
Founded:
2008-01-01
Address:
Newton, Massachusetts, United States
Country:
United States
Website Url:
http://www.karyopharm.com
Total Employee:
251+
Status:
Active
Contact:
+1 617 658 0600
Total Funding:
381.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Mobile Non Scaleable Content
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Board_member
2013-04-01
Board_member
2010-10-01
Advisor
Advisor
Advisor
Advisor
Advisor
Board_member
Current Employees Featured
Sharon Shacham Founder , CSO & President @ Karyopharm Therapeutics
Founder , CSO & President
2009-06-01
Brian Austad SVP, Pharmaceutical Sciences @ Karyopharm Therapeutics
SVP, Pharmaceutical Sciences
2018-02-01
Ronald A. DePinho Co-Founder @ Karyopharm Therapeutics
Co-Founder
Sohanya Cheng SVP Sales & Chief Commercial Officer @ Karyopharm Therapeutics
SVP Sales & Chief Commercial Officer
2021-06-01
Michael Kauffman CEO @ Karyopharm Therapeutics
CEO
2011-11-01
John McCartney Senior Director, Product Leadership @ Karyopharm Therapeutics
Senior Director, Product Leadership
Dilara McCauley Vice President, Product Leadership @ Karyopharm Therapeutics
Vice President, Product Leadership
Wen Chen Senior Director of Pharmaceutical Sciences, Formulation Development @ Karyopharm Therapeutics
Senior Director of Pharmaceutical Sciences, Formulation Development
Founder
Stock Details
Investors List
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - Karyopharm Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Karyopharm Therapeutics
Delphi Ventures
Delphi Ventures investment in Series B - Karyopharm Therapeutics
Delphi Ventures
Delphi Ventures investment in Series B - Karyopharm Therapeutics
Chione
Chione investment in Series A - Karyopharm Therapeutics
Multiple Myeloma Research Foundation
Multiple Myeloma Research Foundation investment in Grant - Karyopharm Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-01-10 | Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer |
Official Site Inspections
http://www.karyopharm.com Semrush global rank: 2.07 M Semrush visits lastest month: 10.09 K
- Host name: 156.218.184.35.bc.googleusercontent.com
- IP address: 35.184.218.156
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York

More informations about "Karyopharm Therapeutics"
About - Karyopharm
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical …See details»
Company Overview – Karyopharm Therapeutics
At Karyopharm, we support a culture of innovation, courage, alignment and accountability, resiliency and energy with our employees and collaborators. Integrity and respect are core to our success. Karyopharm at a Glance. …See details»
Karyopharm Therapeutics Inc. | LinkedIn
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and …See details»
Karyopharm Therapeutics - Crunchbase Company …
Karyopharm Therapeutics is a biopharmaceutical company with a focus on the development of novel drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation. Karyopharm Therapeutics is developing …See details»
Investor Relations | Karyopharm Therapeutics
Dec 9, 2024 Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory …See details»
Karyopharm Therapeutics - The Org
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export …See details»
Investor Relations | Karyopharm Therapeutics - Corporate …
The Board of Directors of Karyopharm Therapeutics (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of …See details»
Karyopharm Therapeutics Inc. Information - RocketReach
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and …See details»
Karyopharm Therapeutics - Overview, News & Similar companies
May 8, 2024 Karyopharm Therapeutics contact info: Phone number: (617) 658-0600 Website: www.karyopharm.com What does Karyopharm Therapeutics do? Karyopharm Therapeutics, …See details»
Karyopharm Announces the Appointment of Lori Macomber as …
15 hours ago Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the …See details»
Our Management Team - Karyopharm
Meet Karyopharm's management team and learn more about their experience and leadership in the pharmaceutical industry.See details»
Karyopharm Therapeutics - Contacts, Employees, Board Members, …
Organization. Karyopharm Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... Karyopharm Therapeutics has …See details»
Karyopharm Therapeutics Mission, Benefits, and Work Culture
Come see what’s going on inside Karyopharm Therapeutics, including the company culture, employee work-life benefits, and business goals. Discover all the key insights that make …See details»
Karyopharm Announces Key Changes to Its Commercial …
NEWTON, Mass., June 8, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today …See details»
Karyopharm Therapeutics Appoints Lori Macomber As CFO
2 hours ago (RTTNews) - Karyopharm Therapeutics Inc. (KPTI), a company focused on novel cancer therapies, said on Thursday that it has appointed Lori Macomber as Chief Financial …See details»
Karyopharm Announces the Appointment of Lori Macomber as …
3 hours ago These and other risks are described under the caption "Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, …See details»
Board of Directors - Karyopharm
Mr. Paulson was appointed President and Chief Executive Officer of Karyopharm in May 2021 and has served as a member of Karyopharm’s Board of Directors since February 2020. He …See details»
Karyopharm appoints new CFO to bolster financial strategy
2 hours ago Karyopharm is known for its pioneering work in oral compounds that target nuclear export dysregulation, a key factor in oncogenesis. Their main product, XPOVIO, has received …See details»
Karyopharm Announces the Appointment of Brendan Strong as …
Dec 9, 2024 "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, …See details»
Karyopharm Announces the Appointment of Lori Macomber as …
3 hours ago NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer …See details»